Irbesartan + Hidroclorotiazida Ratiopharm (Hydrochlorothiazide, Irbesartan)

Irbesartan blocks the AT1 receptors for angiotensin II, preventing vasoconstriction and aldosterone release. This leads to relaxation of blood vessels and reduced sodium and water retention, contributing to lower arterial pressure.

The appropriate dose is determined by the prescribing clinician based on the patient’s blood pressure, renal function, and overall health. Dosage may be adjusted during treatment to achieve target blood pressure goals.

Irbesartan + Hidroclorotiazida Ratiopharm is classified as Pregnancy Category D, indicating potential risk to the fetus. It should be avoided in pregnancy. Limited data are available for breastfeeding; the decision to use it should be made by a healthcare professional weighing benefits and risks.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with single‑agent therapies, the Irbesartan/Hydrochlorothiazide combination offers dual mechanisms—vascular relaxation and diuresis—in a single tablet, which can improve adherence and provide more consistent blood‑pressure control than using each component separately.

Store the tablets at ambient temperature, below 25 °C, in the original packaging. Protect them from moisture and direct sunlight to maintain stability and potency throughout the shelf life.

The medication is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious risks include severe hypotension, acute kidney injury, hyperkalemia, and rare allergic reactions such as angioedema. Patients should be monitored for signs of these conditions, especially during treatment initiation or dose changes.

The combination should be avoided in patients with known hypersensitivity to irbesartan, hydrochlorothiazide, or any excipients, in those with severe renal impairment, hyperkalemia, or in pregnant women. Clinicians should also exercise caution in elderly patients prone to volume depletion.